Advanced Therapy Medicinal Products Market - Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning Review & Global Market Size Forecast to 2032
Overview
Global Advanced Therapy Medicinal Products Market size was valued at USD 16.60 Bn. in 2025 and the total Advanced Therapy Medicinal Products revenue is expected to grow by 13.2 % from 2026 to 2032, reaching nearly USD 39.55 Bn.
Advanced Therapy Medicinal Products Market Overview:
ATMPs (advanced therapeutic medical products) are medicines of human that are based on the genetic, tissue makeup of human beings. It provides the whole new avenues for the treatment of sicknesses which are rare and critical injuries. Medical products in advanced treatment are progressive therapies that rely on high-quality treatment, extensive cell treatment, and tissue-constructed things. As a consequence, the worldwide advanced treatment medical goods market is projected to grow during the forecast period. ATMPs are pharmaceuticals that act on live cells or dynamic hereditary materials to provide innovative therapeutic options for a variety of infections, both acute and chronic.
To know about the Research Methodology :- Request Free Sample Report
Advanced Therapy Medicinal Products Market Dynamics:
A Booming Industry Driven by Innovation and Investment
The introduction of Advanced Therapy Medicinal Products (ATMPs) has changed the pharmaceutical business and the panorama of medical treatment. It has laid the foundation for novel treatments for incurable illnesses and cancers of different kinds. The market is being driven by the success of products like Kymriah, Zolgensma, and others.
This is likely to propel expenditure in advanced treatment research and development for SARS-CoV2 infections. Furthermore, an increasing number of clinical trials including Mesenchymal Stromal/Stem Cells (MSCs) have recently been filed as a novel therapy paradigm for SARS-CoV-2 infection. These treatments have exhibited encouraging outcomes in research programs as a therapeutic method, contributing to the marketspace's organic revenue creation which boosts the Cell Therapy Treatments Market.
The market for advanced treatment medical products has risen exponentially in recent years. This industry is expected to become more competitive as a growing number of businesses enter the market. Furthermore, new Advanced Therapy Medicinal Products (ATMP) approvals have boosted this sector's growth. Market participants are employing a variety of methods in order to maintain their market position. The current trend in this sector is collaborations with contract manufacturing firms. Due to increased Research and Development activity in this sector, contract manufacturing organizations (CMOs) are seeing a surge in demand for their services.
Moreover, tie-ups with Contract research organizations and contract manufacturing organizations are economical, licensed, and offer safety and security towards the end product. Hence, this factor is likely to motivate Advanced Therapy Medicinal Products Market growth in the future.
Gene Therapy Products Market Poised for Growth as Protein and Small Molecule-Based Research Intensifies
Various protein and small molecule-based research and design firms have begun to focus on adoptive cell T treatments. For example, the U.S. FDA approved Bristol Myers Squibb's Abecma (idecabtagene vicleucel) - a cell-based gene therapy medicinal product designed for the treatment of patients with multiple myeloma in March 2021, through a partnership with Bluebird-Bio. As a result, the demand for the Gene Therapy Products Market is increasing.
Investments in Advanced Therapy Medicinal Products and an increase in financing is expected to deliver plenty of growth opportunities in the market. T-cell therapies are supported financially by grants awarded to university hospitals. Some market players have undertaken in-house production of therapies, and several players prefer service from third-party providers, including contract manufacturing organizations. On the other side, numerous companies have marked their presence in the market just by obtaining small and emerging CAR T-cell therapy developers. Some notable and recent examples include the purchases of Kite Pharma by Gilead Life Science, AveXis by Novartis, and Juno Therapeutics by Celgene. Therefore, the factors above boost the market growth.
Advanced Therapy Medicinal Products Market Segment Analysis
The tissue-engineered product segment is anticipated to adhere to the growth of the Advanced Therapy Medicinal Products Market.
Based on the Therapy Type, The tissue-engineered product category led the market accounting for 39.0% of revenue share. The adoption of tissue-engineered products or processes as an important element of medicine and treatment procedures, particularly in therapies that demand functional recovery of any sick or wounded area of the body, may be ascribed to this dominance. The amount of publications, research papers, clinical trials, and translational products has increased dramatically in recent years, indicating that this area has gained substantial popularity which has propelled the Tissue Engineered Products Market. Furthermore, the segment's expansion is aided by ongoing advances in technology and products to advance the tissue engineering process. For example, a group of researchers at the University of Illinois Chicago presented a unique hydrogel-shaped-changing 4D material in February 2021 that can change form in response to physiological inputs.
The CAR-T treatment sector, on the other hand, is getting popular in the market and is anticipated to grow at the strongest rate throughout the projection period. Key firms including Novartis AG, Gilead Sciences, Inc., and Bristol-Myers Squibb are emphasizing increasing the global reach of their CAR-T therapies which increases the demand for the CAR-T Cell Therapies Market. For example, Novartis AG revealed that the Health Sciences Authority has authorized Kymriah as Singapore's first commercially licensed CAR-T treatment. It is expected that the growth by other segments such as cell therapy which is segmented into two different sub-segments i.e. stem cell therapy and non-stem cell therapy. Stem cell therapy promotes the healing response of diseased, injured tissue using stem cells and due to this Stem Cell-based Therapies Market is in demand. There are physical therapy, occupational therapy, speech therapy, and other types of rehabilitation that come under neurological disorder therapies which increases the demand for the neurological disorder therapies market.
Based on the Distribution Channel,
Hospital Pharmacies dominated the market in the year 2025 with almost 53% in terms of revenue share and is expected to dominate the ATMP market during the forecast period. Other segments such as retail pharmacies and online pharmacies are gaining some popularity in the market. The expansion of Retail pharmacies is expected throughout the forecast period, particularly for less complex products. Online pharmacies are leveraging and increasing its demand, as the convenience and accessibility to reach patients in remote areas is also increasing. As a result, the demand for the Advanced Therapy Medicinal Products(ATMP) Industry and Advanced Therapy Clinical Trials Market as well.
Global Advanced Therapy Medicinal Products Market Recent Development
| Date | Company | Development | Impact |
|---|---|---|---|
| 19 February 2026 | Eli Lilly and Company | Eli Lilly announced the strategic acquisition of Orna Therapeutics to significantly advance its proprietary portfolio of specialized cell and gene therapies. | This acquisition expands the company’s pipeline into novel RNA-based advanced therapy medicinal products (ATMPs), bolstering therapeutic solutions for complex oncological and genetic disorders. |
| 12 February 2026 | FUJIFILM Diosynth Biotechnologies | The company successfully expanded its UK facility to optimize its large-scale biologics and cell therapy manufacturing network. | The upgraded infrastructure addresses global supply constraints by accelerating CDMO clinical-to-commercial capabilities for advanced cellular therapies. |
| 11 February 2026 | Celyad Oncology | Celyad Oncology finalized the strategic sale of its specialized C-CATHez catheter technology to focus resources entirely on unlocking its cell therapy IP pipeline. | The deal successfully extends the company’s financial cash runway through Q3-2026, safeguarding key R&D operations for next-generation ATMP innovations. |
| 14 May 2025 | Fondazione Telethon | Fondazione Telethon secured historical concurrent regulatory approvals from the FDA and EMA for etuvetidigene autotemcel (Waskyra) to treat Wiskott–Aldrich syndrome. | This landmark approval marks the first time a non-profit organization has commercialized an authorized gene therapy product for a rare genetic disease. |
Advanced Therapy Medicinal Products Market Regional Insights:
North American region dominated the market in the year 2025 and is estimated to hit the market growth of the Advanced Therapy Medical Products Market with 49% of revenue share in the year 2025. The region's dominance in the market for advanced treatment medical goods is due to a favorable regulatory environment, successful product launches, and significant expenditures in research and development. Furthermore, the fast-growing majority of clinical investigations in this novel therapeutic method in the United States contribute to regional growth.
In March 2021, the United States contributed around 57.0% of all the current immunotherapy trials worldwide. This high share implies that the market is seeing an increase in investment, which is driving revenue creation and can boost the Rare Disease Therapies Market. The Asia-Pacific region is expected to reach a CAGR of over 9% during the forecast period.
Countries including Japan, China, and South Korea are leading in the recent global growth of the Asia-Pacific for the ATMP market as the manufacturing of these products increases the demand for the ATMP Manufacturing Processes Market. Due to a robust research basis for innovative treatments, Europe held the second-largest share of the market in 2025. Further, the presence of prominent players in the regions is estimated to fuel the market growth in the forecast period.
The objective of the report is to present a comprehensive analysis of the Advanced Therapy Medicinal Products Market including all the stakeholders of the End User. The past and current status of the End User with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the End User with a dedicated study of key players that includes market leaders, followers, and new entrants by region.
PORTER, SVOR, and PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the End User to the decision-makers.
The report also helps in understanding the Market dynamics, and structure by analyzing the market segments and projecting the Advanced Therapy Medicinal Products Market size. Clear representation of competitive analysis of key players by type, price, financial position, Derivatives portfolio, growth strategies, and regional presence in the Advanced Therapy Medicinal Products Market makes the report an investor’s guide.
Advanced Therapy Medicinal Products Market Scope: Inquire before buying
| Advanced Therapy Medicinal Products Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | USD 16.60 Bn. |
| Forecast Period 2026 to 2032 CAGR: | 13.2% | Market Size in 2032: | USD 39.55 Bn. |
| Segments Covered: | by Therapy Type | Cell Therapy Stem Cell Therapy Non-stem Cell Therapy CAR-T Therapy Gene Therapy Tissue Engineered Product |
|
| by Disease Type | Alzheimer’s Cystic Fibrosis Muscular Dystrophies Hemophilia |
||
| by Distribution Channel | Hospital Pharmacy Retail Pharmacy Online Pharmacy |
||
Advanced Therapy Medicinal Products Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Advanced Therapy Medicinal Products Market Key Players
North America
1. Sarepta Therapeutics, Inc. – United States
2. Bluebird Bio, Inc. – United States
3. Rocket Pharmaceuticals, Inc. – United States
4. Regenxbio Inc. – United States
5. Krystal Biotech, Inc. – United States
Europe
1. Orchard Therapeutics plc – United Kingdom
2. uniQure N.V. – Netherlands
Asia Pacific
1. Takara Bio Inc. – Japan
2. Cell Therapy & CAR-T Therapy Developers
These companies engineer immune cells or other therapeutic cells to treat cancers and severe diseases.
North America
1. Gilead Sciences, Inc. (Kite Pharma) – United States
2. Bristol Myers Squibb Company – United States
3. Fate Therapeutics, Inc. – United States
4. Cellectis Inc. – United States
Europe
1. Cellectis S.A. – France
2. Novartis AG – Switzerland
Asia Pacific
1. JW Therapeutics – China
2. Legend Biotech Corporation – China
3. Tissue Engineering & Regenerative Medicine Companies
These companies develop engineered tissues, regenerative therapies, and stem-cell-based products for tissue repair and organ regeneration.
North America
1. Organogenesis Holdings Inc. – United States
2. Vericel Corporation – United States
3. Mesoblast Limited – United States operations/Australia
Europe
1. CO.DON AG – Germany
2. TiGenix (Takeda Group) – Belgium
Asia Pacific
1. JCR Pharmaceuticals Co., Ltd. – Japan
4. Gene Editing & Next-Generation Cell Engineering Companies
These companies use CRISPR, TALEN, base editing, and other advanced genome engineering technologies.
North America
1. Editas Medicine, Inc. – United States
2. Intellia Therapeutics, Inc. – United States
3. Beam Therapeutics Inc. – United States
4. Caribou Biosciences, Inc. – United States
Europe
1. CRISPR Therapeutics AG – Switzerland
2. Cellectis S.A. – France
Asia Pacific
1. ToolGen Inc. – South Korea
5. ATMP Manufacturing, Viral Vector & Bioprocessing Companies
These companies provide manufacturing, viral vector production, CDMO services, and bioprocessing solutions supporting ATMP commercialization.
North America
1. Thermo Fisher Scientific Inc. – United States
2. Catalent, Inc. – United States
3. Lonza Bioscience US – United States
Europe
1. Lonza Group AG – Switzerland
2. Oxford Biomedica plc – United Kingdom
3. Sartorius AG – Germany
Asia Pacific
1. FUJIFILM Diosynth Biotechnologies – Japan
2. WuXi Advanced Therapies – China
Frequently Asked Questions:
1] What segments are covered in the Global Advanced Therapy Medicinal Products Market report?
Ans. The segments covered in the Advanced Therapy Medicinal Products Market report are based on Therapy Type, Disease Type, and Distribution Channel, and Region.
2] Which region is expected to hold the highest share of the Global Advanced Therapy Medicinal Products Market?
Ans. The North American region is expected to hold the highest share of the Advanced Therapy Medicinal Products Market. The United States is expected to lead the North American market and is expected to grow at a CAGR of 8.2% over the forecast period.
3] What is the market size of the Global Advanced Therapy Medicinal Products Market by 2032?
Ans. The market size of the Advanced Therapy Medicinal Products Market by 2032 is expected to reach US$ 39.55 Bn.
4] What is the forecast period for the Global Advanced Therapy Medicinal Products Market?
Ans. The forecast period for the Advanced Therapy Medicinal Products Market is 2026-2032
5] What was the market size of the Global Advanced Therapy Medicinal Products Market in 2025?
Ans. The market size of the Advanced Therapy Medicinal Products Market in 2025 was valued at US$ 16.60 Bn.